The Need for a New Targeting Approach
The Life Sciences commercial model has moved decisively from volume-and-coverage to relevance-and-outcomes. HCP expectations, payer demands for value evidence, and the permanent rise of hybrid engagement mean that “more calls” no longer equals “more impact.” Instead, companies must answer three questions in near real-time: Who to prioritize, what to deliver, and how to measure impact. That requires an integrated data backbone, robust analytics, and operational processes that turn insight into action at the time of engagement. 84% of physicians say they prefer to maintain or increase the share of virtual interactions (i.e., hybrid engagement is now the norm).
Read more in our latest Point of View here: Unlocking NextGen HCP Targeting in Life Sciences Through Data and Analytics
